[go: up one dir, main page]

MA33725B1 - Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds - Google Patents

Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds

Info

Publication number
MA33725B1
MA33725B1 MA34835A MA34835A MA33725B1 MA 33725 B1 MA33725 B1 MA 33725B1 MA 34835 A MA34835 A MA 34835A MA 34835 A MA34835 A MA 34835A MA 33725 B1 MA33725 B1 MA 33725B1
Authority
MA
Morocco
Prior art keywords
compound
pgds
inhibitors
phenyloxadiazole
derivatives
Prior art date
Application number
MA34835A
Other languages
Arabic (ar)
English (en)
Inventor
Harpal S Gill
George Lee
Andrea Hillegass
Christopher L Vandeusen
Franz J Weiberth
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33725B1 publication Critical patent/MA33725B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Cette invention porte sur un composé de la formule (i) : dans laquelle r1, r2 et r3 sont tels que définis par les présentes, sur une composition pharmaceutique comportant le composé, sur des intermédiaires et sur des procédés de fabrication desdits composés, et sur l'utilisation du composé pour traiter des troubles allergiques et/ou inflammatoires, en particulier des troubles tels que la rhinite allergique, l'asthme, la broncho-pneumopathie obstructive chronique (copd) et la dégénérescence maculaire liée à l'âge (amd).
MA34835A 2009-10-08 2012-05-04 Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds MA33725B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24969309P 2009-10-08 2009-10-08
FR1056094 2010-07-26
PCT/US2010/051727 WO2011044307A1 (fr) 2009-10-08 2010-10-07 Dérivés de phényloxadiazole en tant qu'inhibiteurs de pgds

Publications (1)

Publication Number Publication Date
MA33725B1 true MA33725B1 (fr) 2012-11-01

Family

ID=43606440

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34835A MA33725B1 (fr) 2009-10-08 2012-05-04 Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds

Country Status (21)

Country Link
US (5) US9469627B2 (fr)
EP (1) EP2486024B1 (fr)
JP (2) JP5753176B2 (fr)
KR (1) KR101701135B1 (fr)
CN (3) CN107875155A (fr)
AR (1) AR078552A1 (fr)
AU (1) AU2010303439B2 (fr)
BR (1) BR112012007635B1 (fr)
CA (1) CA2776242C (fr)
DK (1) DK2486024T3 (fr)
ES (1) ES2543011T3 (fr)
IL (1) IL218967A (fr)
MA (1) MA33725B1 (fr)
MX (1) MX2012003021A (fr)
NZ (1) NZ599099A (fr)
PH (1) PH12012500676A1 (fr)
RU (2) RU2572608C2 (fr)
SG (1) SG179199A1 (fr)
TW (1) TWI508960B (fr)
UY (1) UY32938A (fr)
WO (1) WO2011044307A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG179199A1 (en) 2009-10-08 2012-04-27 Sanofi Sa Phenyloxadiazole derivatives as pgds inhibitors
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
US20210238162A1 (en) 2015-12-17 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
MA48798B1 (fr) * 2017-05-22 2023-10-31 Egyt Gyogyszervegyeszeti Gyar Procédé de production d'ozanimod
BR112019026452A2 (pt) 2017-06-13 2020-07-14 Glaxosmithkline Intellectual Property Development Limited compostos químicos como inibidores de h-pgds
WO2019116256A1 (fr) 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Pyridines fusionnées agissant en tant qu'inhibiteurs de h-pgds
UY38455A (es) 2018-11-08 2020-05-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
WO2021256569A1 (fr) * 2020-06-19 2021-12-23 佐藤製薬株式会社 Composés cycliques condensés qui inhibent la h-pgds
CA3240926A1 (fr) 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Derive d'azaindole inhibant h-pgds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
DE10117823A1 (de) 2001-04-10 2002-10-17 Merck Patent Gmbh Oxalsäurederivate
CA2479352A1 (fr) * 2002-03-19 2003-09-25 Ono Pharmaceutical Co., Ltd. Composes d'acide carboxylique et medicaments renfermant les composes comme principe actif
AU2003258278A1 (en) 2002-08-16 2004-03-03 Aventis Pharmaceuticals Inc. Assaying compounds or agents for microsomal prostaglandin E synthase or hematopoietic prostaglandin D synthase activity
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
WO2005094805A1 (fr) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. Dérivé imine et dérivé amide
TW200538118A (en) * 2004-04-21 2005-12-01 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
JP5209181B2 (ja) * 2005-03-15 2013-06-12 富士フイルム株式会社 化合物、組成物、位相差板、楕円偏光板および液晶表示装置
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
CN100556905C (zh) * 2005-09-08 2009-11-04 国家南方农药创制中心江苏基地 吡唑酰胺类化合物及其中间体和以该类化合物为活性成分的有害生物防治剂
WO2007039177A2 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
AR056871A1 (es) * 2005-10-04 2007-10-31 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
WO2008075172A2 (fr) 2006-12-19 2008-06-26 Pfizer Products Inc. Dérivés de nicotinamide
WO2008104869A1 (fr) * 2007-02-26 2008-09-04 Pfizer Products Inc. Composés hétérocycliques utiles dans le traitement de maladies et de conditions
PT2142516E (pt) 2007-03-30 2013-03-07 Sanofi Sa Compostos de hidrazida de pirimidina como inibidores de pgds
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
TW201034675A (en) * 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
US9058931B2 (en) 2009-01-12 2015-06-16 The United States Of America, As Represented By The Secretary Of The Navy Composite electrode structure
SG179199A1 (en) 2009-10-08 2012-04-27 Sanofi Sa Phenyloxadiazole derivatives as pgds inhibitors

Also Published As

Publication number Publication date
RU2015151129A3 (fr) 2019-07-17
JP5897186B2 (ja) 2016-03-30
CA2776242A1 (fr) 2011-04-14
BR112012007635A2 (pt) 2017-06-20
WO2011044307A1 (fr) 2011-04-14
US20120190695A1 (en) 2012-07-26
US20230190747A1 (en) 2023-06-22
EP2486024A1 (fr) 2012-08-15
EP2486024B1 (fr) 2015-04-22
KR20120094910A (ko) 2012-08-27
CA2776242C (fr) 2014-09-02
TWI508960B (zh) 2015-11-21
CN102666508A (zh) 2012-09-12
KR101701135B1 (ko) 2017-02-01
NZ599099A (en) 2013-05-31
CN107875155A (zh) 2018-04-06
UY32938A (es) 2011-05-31
AU2010303439A1 (en) 2012-04-26
JP2013507376A (ja) 2013-03-04
US9937175B2 (en) 2018-04-10
AU2010303439B2 (en) 2015-10-29
TW201127835A (en) 2011-08-16
US9469627B2 (en) 2016-10-18
IL218967A (en) 2015-05-31
PH12012500676A1 (en) 2015-06-03
BR112012007635B1 (pt) 2019-07-09
US20170231990A1 (en) 2017-08-17
RU2012118756A (ru) 2013-11-20
SG179199A1 (en) 2012-04-27
RU2015151129A (ru) 2019-01-15
CN106943407A (zh) 2017-07-14
IL218967A0 (en) 2012-07-31
MX2012003021A (es) 2012-04-10
JP5753176B2 (ja) 2015-07-22
HK1173441A1 (en) 2013-05-16
JP2015178516A (ja) 2015-10-08
ES2543011T3 (es) 2015-08-13
DK2486024T3 (en) 2015-07-27
AR078552A1 (es) 2011-11-16
US20190262338A1 (en) 2019-08-29
RU2572608C2 (ru) 2016-01-20
US20190000845A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
MA33725B1 (fr) Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds
MA31326B1 (fr) Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds
MA29925B1 (fr) Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds
NO20084005L (no) Aminderivater
WO2009069032A3 (fr) Nouveaux agonistes des récepteurs des glucocorticoïdes
TW200612911A (en) Compounds for the treatment of inflammatory disorders
TW200616620A (en) Compounds for the treatment of inflammatory disorders
TW200736248A (en) Compounds for the treatment of inflammatory disorders
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MX2009008773A (es) Derivados de 3,4-dihidro-1,4-benzoxazina,3,4-dihidro-1,4-benzotiaz ina y 1,2,3,4-tetrahidro-quinoxalina como agonistas de adrenoreceptores alfa2c.
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
NO20090646L (no) Xinafoatsalt av en substituert 5-oksazol-2-yl-kinolinforbindelse
NO20092413L (no) Pyrazolanaloger
TW200640905A (en) Monopotassium salt of an IκB kinase inhibitor
UA95861C2 (en) Glucocorticoid receptor agonists
NO20064806L (no) Formamidderivater anvendelige som adenoceptor
TH105528A (th) สารประกอบไพริมิดีน เอไมด์ ที่เป็นสารยับยั้งพรอสตาแกลนดิน
NO20064805L (no) Sammensetninger for behandling av sykdommer
MA28302A1 (fr) Derives de sulfonamides pour le traitement de maladies
CN109563093A (zh) 作为crth2抑制剂的三并环类化合物
TN2010000612A1 (fr) Derives de triazole utiles pour le traitement de maladie
TH87151B (th) สารประกอบเคมี
TH126452A (th) อนุพันธ์ฟูโรไพริมิดีนไดโอนในรูปตัวควบคุม trpa1
TH105528B (th) สารประกอบไพริมิดีน เอไมด์ ที่เป็นสารยับยั้งพรอสตาแกลนดิน